Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm
NCT ID: NCT00276315
Last Updated: 2020-04-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
332 participants
INTERVENTIONAL
2005-12-31
2007-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Botulinum Toxin A in the Treatment of Hemifacial Spasm
NCT03306940
Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm
NCT00234507
Study of Abobotulinum Toxin Versus Neubotulinum Toxin Injection For Hemifacial Spasm in Thai Patients
NCT04589364
Post Marketing Surveillance Study of Dysport
NCT00210431
Dysport in the Treatment of Glabellar Lines in Chinese Subjects
NCT02450526
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Botulinum toxin type A
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cohen scale ≥ to grade II
Exclusion Criteria
* Hemifacial spasm secondary to facial palsy
* Previous alcohol or phenol injections or surgical therapy of the facial muscles
* Requirement for botulinum toxin injection to site(s) of the body other than in this study
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ipsen
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ipsen Medical Director
Role: STUDY_DIRECTOR
Ipsen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Neurology Department, Peking Union Medical College Hospital
Beijing, , China
Neurology Department, Guangdong Provincial People's Hospital
Guangdong, , China
Neurology Department, Sir Run Run Shaw Hospital, Zhejiang University
Hangzhou, , China
Neurology Department, Shanghai Ruijin Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A-38-52120-074
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.